NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution ...

Abstract: In this work, we propose a novel hybrid architecture for epileptic seizure prediction, utilizing a deep learning approach by stacking the convolutional neural network (CNN) and bidirectional ...

Xenon Pharmaceuticals XENE reported a loss of $1.17 per share in the first quarter of 2026, matching the Zacks Consensus ...

In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst ...

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional Phase 3 studies of azetukalner continue to enroll in ep ...

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional ...

Objectives To develop a working definition of successful transition from paediatric to adult epilepsy services, assess transition success, identify predictors and determine whether success is ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Anna Wenner A former pick, the Beyond XP5000 Plastic-Backed Adult Brief, has ...

Brain cancer is one of the deadliest diseases — and early detection is crucial for better outcomes. There are obvious symptoms like sudden, severe headaches and dizziness, while subtle signs such as ...

NeuroPace, Inc. , a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a major milestone in its clinical evidence program with the ...

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in ...